AcelRx Pharmaceuticals to Host Investor Day on June 27, 2013
REDWOOD CITY, Calif., June 21, 2013
REDWOOD CITY, Calif., June 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, will host an Investor Day on Thursday, June 27,
2013, from 9:00 a.m. to 11:00 a.m. EDT (6:00 a.m. to 8:00 a.m. PDT) at the 21
Club, 21 West 53^rd Street, New York, NY.
Members of the AcelRx management team will present insights on the Company's
Sufentanil NanoTab PCA System Phase 3 clinical trial results and discuss plans
related to hospital formulary adoption and commercialization. In addition,
thought leaders who treat post-operative pain in the hospital setting will
discuss their experience with and perspectives on the Sufentanil NanoTab PCA
System. Breakfast will be served for meeting attendees from 8:00 a.m. to 9:00
a.m. and a link to the live webcast will be available on the Investors page of
the Company's website at www.acelrx.com beginning at 9:00 a.m. EDT. An archive
of the webcast will be available shortly after the event through the Investors
page at www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the
treatment of acute and breakthrough pain. AcelRx's lead product candidate,
the Sufentanil NanoTab PCA System, is designed to solve the problems
associated with post-operative intravenous patient-controlled analgesia which
has been shown to cause harm to patients following surgery because of the side
effects of morphine, the invasive IV route of delivery and the complexity of
infusion pumps.The NanoTab System has successfully completed all three of its
planned Phase 3 clinical trials and a New Drug Application submission is
planned for the third quarter of 2013. AcelRx has announced positive top-line
results for a Phase 2 trial for ARX-04, a sufentanil formulation for the
treatment of moderate-to-severe acute pain, funded through a grant from U.S.
Army Medical Research and Materiel Command. The company has two additional
pain treatment product candidates, ARX-02 and ARX-03, which have completed
Phase 2 clinical development. For additional information about AcelRx's
clinical programs please visit www.acelrx.com.
Forward Looking Statements
This press release contains forward-looking statements, including, but not
limited to, statements related to the Company's Sufentanil NanoTab PCA System
Phase 3 clinical trial results, planned New Drug Application submission, the
Company's plans related to hospital formulary adoption and commercialization
as well as planned or anticipated future clinical development of AcelRx
Pharmaceuticals' product candidates, and the therapeutic potential of AcelRx
Pharmaceuticals' product candidates. These forward-looking statements are
based on AcelRx Pharmaceuticals' current expectations and inherently involve
significant risks and uncertainties. AcelRx Pharmaceuticals' actual results
and the timing of events could differ materially from those anticipated in
such forward-looking statements as a result of these risks and uncertainties,
which include, without limitation, risks related to: the success, cost and
timing of AcelRx Pharmaceuticals' product development activities and clinical
trials; the market potential for its product candidates; and other risks
detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals' U.S.
Securities and Exchange Commission filings, including its Quarterly Report on
Form 10-Q filed with the SEC on May 8, 2013. AcelRx Pharmaceuticals
undertakes no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future events or
changes in its expectations.
SOURCE AcelRx Pharmaceuticals, Inc.
Contact: COMPANY CONTACT, Jim Welch, Chief Financial Officer, AcelRx
Pharmaceuticals, Inc., 1-650-216-3511; INVESTOR MEETING CONTACT, Robert H. Uhl
(email@example.com), Managing Director, Westwicke Partners, LLC,
Press spacebar to pause and continue. Press esc to stop.